Related Experiment Video
Updated: May 9, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Proof of Concept: Drug Selection? Or Dose Selection? Thoughts on Multiplicity Issues
Qian H Li1, Qiqi Deng2, Naitee Ting3
1Global Biometrics and Data Sciences, Bristol Myers Squibb - Global Biopharmaceutical Company, NewYork, USA.
Abstract:
In new drug development process, one of the most important milestones for a drug candidate is to establish Proof of Concept (PoC) at early Phase II stage. Among many challenges in PoC clinical trial design and analysis, the application of multiplicity comparison procedures (MCP) is frequently discussed when multiple doses or drugs are included in one PoC study. In such discussion, one fundamental question of applying multiplicity adjustment is which error one should consider to control and at what level. Should it be the experiment-wise error or the compound-wise error? In this paper, the multiplicity issues in two cases of PoC studies are used as examples to discuss the concept of different types of error and the level of the error rate control. With a clear understanding of the type of error and error rate control, the debate of applications of the multiplicity adjustment procedures in the PoC studies can be reconciled.
Related Concept Videos
Drug Discovery: Overview
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioequivalence of Drugs: Drugs with Multiple Indications
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
Pharmacokinetic–Pharmacodynamic Relationship: Problems

